We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Glanbia Plc | LSE:GLB | London | Ordinary Share | IE0000669501 | ORD EUR0.06 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.05 | -7.47% | 13.00 | 13.00 | 15.10 | 13.00 | 13.00 | 13.00 | 13,758 | 12:40:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.43B | 344.5M | 1.2652 | 10.28 | 3.83B |
Glanbia launches further share buy-back of up to €50m
16 December 2024, Glanbia plc, the Better Nutrition company, (the "Company" or the "Group") announces that, from today, it will commence a share buy-back programme of up to €50 million in total value in Glanbia plc ordinary shares ("Shares"). The purpose of the share buy-back programme is to reduce the share capital of the Company (any Shares repurchased for this purpose will be cancelled). This programme is being carried out under the €50 million share buyback authority announced by the Company on 6 November 2024.
Details of the programme
The Company has entered into an agreement with J&E Davy ("Davy") to act as principal in relation to the purchase of the Company's Shares, within certain pre-set parameters.
The programme will run from 16 December 2024, through to 30 June 2025, unless otherwise terminated in accordance with the Company's agreement with Davy and prevailing authority.
Under the terms of the agreement, Davy will make purchases of the Shares under the buy-back programme independently of, and uninfluenced by, the Company. Purchases may continue during any closed period to which the Company is subject. The Company confirms that it currently has no unpublished inside information.
The share buy-back programme will be conducted within the limitations of the Company's general authority to repurchase shares as set out in Resolution 11 approved by the Company's shareholders at the 2024 Annual General Meeting ("AGM") on 1 May 2024 up to a maximum of 10% of the issued share capital of the Company as at 6 March 2024, being 26,489,128 ordinary shares, which has been reduced by 4,264,456 ordinary shares to 22,224,672 ordinary shares as a consequence of the part of the €100 million buyback announced by the Company on 28 February 2024 completed between 1 May 2024 and 26 June 2024 and 14 August 2024 and 2 December 2024. Following the expiry of the 2024 AGM repurchase authority, the continuation of the buyback will be conditional on the shareholder approval of a repurchase general authority at the AGM on 30 April 2025.
The programme will be conducted in accordance with Chapter 9 of the Euronext Dublin Listing Rules and the relevant provisions of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation (EU) 2016/1052 (also as in force in the United Kingdom ("UK"), from time to time, including, where relevant, pursuant to the UK's Market Abuse (Amendment) (EU Exit) Regulations 2019) as well as the rules of the Central Bank of Ireland.
ENDS
For further information contact:
Glanbia plc +353 56 777 2200
Mark Garvey, Group Finance Director
Liam Hennigan, Group Secretary & Head of Investor Relations: +353 86 046 8375
Martha Kavanagh, Director of Corporate Affairs: +353 87 646 2006
Davy
Ivan Murphy/Ronan Veale +353 1 679 7788
1 Year Glanbia Chart |
1 Month Glanbia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions